Shares of Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF – Get Rating) dropped 9.8% on Thursday . The stock traded as low as $0.86 and last traded at $0.92. Approximately 927,361 shares were traded during mid-day trading, an increase of 137% from the average daily volume of 390,616 shares. The stock had previously closed at $1.02.
The company has a market cap of $24.47 million, a price-to-earnings ratio of -1.30 and a beta of 1.83.
Can-Fite BioPharma (NYSEAMERICAN:CANF – Get Rating) last announced its earnings results on Thursday, May 26th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. Can-Fite BioPharma had a negative net margin of 1,478.90% and a negative return on equity of 145.21%. The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.20 million. As a group, equities research analysts anticipate that Can-Fite BioPharma Ltd. will post -0.07 EPS for the current year.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
See Also
- Get a free copy of the StockNews.com research report on Can-Fite BioPharma (CANF)
- Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
- MarketBeat: Week in Review 6/27 – 7/1
- Accolade Moves Higher But Growth Is Slowing
- ZIM Integrated Shipping Services (ZIM): Don’t Miss This Dividend
- RH Gives Good Reason To Get Defensive
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
